We are interested in translating findings of pharmacological lifespan extensions in laboratory animals into humans. Our current projects involve pharmacological inhibition of the mechanistic (mammalian) Target Of Rapamycin (mTOR). mTOR inhibition with rapamycin increases cerebral blood flow (CBF) in mouse models of Alzheimer's Disease (AD) and improves cognition. Our preliminary data suggest similar cognitive effects in humans. Our preliminary data also indicates that rapamycin constricts peripheral vessels in humans but may improve muscle performance (walking speed) in 'oldest old' humans. We are examining these effects in older humans (age 75-95). We hypothesize that RAPA effects on the cerebral and peripheral vasculatures are discordant, but that the cognitive and physical function effects of RAPA are universally beneficial.
Kellogg DL Jr, Zhao JL, Wu Y, Johnson JM. Nitric oxide and receptors for VIP and PACAP in cutaneous active vasodilation during heat stress in humans. J Appl Physiol (1985). 2012 Nov;113(10):1512-8.
Kellogg DL Jr, Zhao JL, Wu Y, Johnson JM. Antagonism of soluble guanylyl cyclase attenuates cutaneous vasodilation during whole body heat stress and local warming in humans. J Appl Physiol (1985). 2011 May;110(5):1406-13.
Kellogg DL Jr, Zhao JL, Wu Y, Johnson JM. VIP/PACAP receptor mediation of cutaneous active vasodilation during heat stress in humans. J Appl Physiol (1985). 2010 Jul;109(1):95-100.
Johnson JM, Kellogg DL Jr. Thermoregulatory and thermal control in the human cutaneous circulation. Front Biosci (Schol Ed). 2010 Jun 1;2:825-53.
Johnson JM, Kellogg DL Jr. Local thermal control of the human cutaneous circulation. J Appl Physiol (1985). 2010 Oct;109(4):1229-38.